Postsurgical Management of Differentiated Thyroid Cancer in China.

Wei-Jun Wei, Guo-Qiang Zhang, Quan-Yong Luo

Journal: Trends in endocrinology and metabolism: TEM 2018;29(2):71-73

PMID: 29150318

Full Text on Elsevier Science View on PubMed

Abstract

Postsurgical management of differentiated thyroid cancer in China has gained a great success in the last twenty years, but there are still gaps to be filled. Here, we briefly review the current status and also extend an outlook for future development.

Address: Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China; Shanghai Jiao Tong University School of Medicine, Shanghai, China; Co-first authors contributed equally.; Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China; Co-first authors contributed equally.; Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. Electronic address: [email protected].

DOI: 10.1016/j.tem.2017.10.008

Link outs

Free resources

Medical:

https://medlineplus.gov/thyroidcancer.html

Other Literature Sources:

https://scite.ai/reports/29150318

Subscription / membership required

Full Text Sources:

MeSH Terms: Adenocarcinoma, Follicular, Antineoplastic Agents, Carcinoma, Papillary, China, Humans, Immunotherapy, Iodine Radioisotopes, MAP Kinase Kinase Kinases, Protein Kinase Inhibitors, Thyroid Cancer, Papillary, Thyroid Neoplasms